HORSHAM, Pa., Sept. 23, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatri
Janssen Biotech, Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved REMICADE (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate respon
AMSTERDAM, September 27, 2011 /PRNewswire/ - Aclidinium Demonstrates Improved Lung Function, Symptom Control and Quality of Life for Chronic Obstructive Pulmonary Disease (COPD) Patients Almirall, S.A. (ALM.MC) today announced results from …
HORSHAM, Pa., Sept. 28, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that STELARA® (ustekinumab) has been awarded the prestigious 2011 Prix Galien USA Award in the category of Best Biotechnology Product. The Prix Galien USA Award recogniz